Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897285 | 1.00 | CYP11B2 (0.60) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Hydrochloric Acid SCHEMBL1739285 | 0.98 | CYP11B2 (0.58) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Hydrochloric Acid SCHEMBL21641116 | 0.98 | CYP11B2 (0.58) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL5939874 | 0.89 | CYP11B2 (0.53) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL5937528 | 0.89 | CYP11B2 (0.53) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Hydrochloric Acid SCHEMBL30574215 | 0.87 | CYP11B2 (0.51) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL717702 | 0.85 | CYP11B2 (0.62) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL19566656 | 0.85 | CYP11B2 (0.62) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Trifluoroacetic Acid SCHEMBL31126136 | 0.84 | KDM4E (0.48) | CYP11B2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| Hydrochloric Acid SCHEMBL2091699 | 0.83 | CYP11B2 (0.61) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-118878514-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-111712502-B | Substituted azetidine dihydro-thienopyrimidines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | CYP11B2 1577/4885CHRNB2 4737/4885CHRNA4 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.